ABC-12
Exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine.
The aim of our study, known as ABC-12 is to analyse the bacteria that normally live in our bowel and mouth. We will be looking to try and find out whether this has an effect on how well cancer responds to treatment and how long life expectancy will be.
Researchers have found that sometimes the body’s own immune system may slow down or control cancer growth. Sometimes this natural immune system response stops and the cancer is not killed by our own immune system and in some patients, cancer cells and immune cells start to express signals that stop the body’s immune system from killing the cancer.
In this study we are using a new drug, durvalumab, to try and block this signal to increase the immune response. Durvalumab is an antibody (a protein produced by the body’s defence system) and it is hoped that by blocking this signal, the immune cells will once again be able to prevent or slow down cancer growth.
Information
| Chief Investigator(s) | |
|---|---|
| Funder(s) |
AstraZeneca |
| Sponsor | The Christie NHS Foundation Trust |
| ISRCTN | 11210442 |
Key facts
| Start date | 1 Nov 2023 |
|---|---|
| End date | 31 Jul 2026 |
| Grant value | £1,144,044 |
| Status |
|
